Kane Biotech Inc
🇨🇦XTSX.KNECanadaHealthcare
PriceCA$0.030.00 (0%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 4
- Medium: 2
- Low: 0
Financial leverage: a sudden drop below its trailing quarter average
P/B ratio: a sudden drop below its trailing quarter average
Gross margin: collapsed against the prior period
Net margin: collapsed against the prior period
Net income: crossed zero, from positive to negative
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- TSX Venture Exchange . XTSX
- Type
- Stock
- ISIN
- CA4838092084
- CUSIP
- 483809208
Company
- Employees
- 0
- Headquarters
- Winnipeg, Canada
- Website
- https://kanebiotech.com
Market
- Shares outstanding
- 205.1M
- Market cap
- CA$4.99M
Highlights
No high and low reported for today's session.
- Market cap
- CA$4.99M
- EPS LTM
- -CA$0.02calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -1.53calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- 0%
Fundamentals (LTM)
- Revenue
- CA$1.85M+460%up year on year
- Net income
- -CA$3.26M-167.46%down year on year
- Gross margin
- 25.34%-40.76%down year on year
- Free cash flow
- -CA$2.98M+36.32%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Kane Biotech Inc is a company in the healthcare sector, listed on TSX Venture Exchange (Canada) under the ticker KNE. Its market capitalisation is CA$4.99M, from 205.1M shares outstanding, as of . Across the 250 trading sessions to the shares traded between CA$0.02 and CA$0.05, and the last close of CA$0.03 sits 33% of the way up that range. The company is headquartered in Winnipeg, Canada.
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate Acne Vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.